AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 2 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Oct 1- Open
- $8.52
- 52-wk high
- $12.43
- High
- $8.88
- 52-wk low
- $1.95
- Low
- $8.52
- Prev close
- $8.52
- Mkt cap
- $9.36B
- Volume
- 8.37M
- Fwd P/E
- 123.5x
- Beta
- 0.14
- P/S
- 56.5x
- Profit margin
- +0.0%
- Op margin
- -120.4%
- ROE
- +0.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about IBRX filings
Are insiders buying or selling Immunitybio Inc (IBRX) stock?
Neither. Immunitybio Inc (IBRX) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded IBRX recently?
None. No member of Congress disclosed a IBRX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this IBRX smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- TS
Two Sigma
$63.5M
added
- MI
Millennium
$38.0M
added
- DS
D.E. Shaw
$96.4M
bought
What insiders are doing
How top traders are positioned
No tracked top-trader positions in IBRX right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in $0.01 a share above what analysts expected.
Earnings per share
-$0.09 expected
Reports Nov 3, 2026, in 33 days
Estimates as of Sep 29, 2026
EPS expected
-$0.09 to $0.00
Revenue expected
4 analysts
Last 30 days
Analysts raising estimates
Financials
Is the business strong?
This company is running thin margins.
- Net margin
- 0.0%
- Forward P/E
- 123.46
- Market cap
- $9.4B
Valuation
- P/S56.45
Quality
- Operating margin-120.4%
- ROE0.0%
- ROA-30.5%
Growth
- Beta0.14
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace